Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pioglitazone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    191 result(s) found for: pioglitazone. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-003822-80 Sponsor Protocol Number: 04/035 Start Date*: 2005-01-12
    Sponsor Name:The Leeds Teaching Hospitals NHS Trust
    Full Title: Modulation of Sympathetic Nerve Activity By Pioglitazone In Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002940-82 Sponsor Protocol Number: CLAF237A2355 Start Date*: 2004-12-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with combination therapy of LAF237 and pioglitazone to LAF237 monotherapy or pioglitazon...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000694-30 Sponsor Protocol Number: 01-05-TL-322OPI-001 Start Date*: 2006-09-21
    Sponsor Name:Takeda Europe Research & Development Centre Ltd.,
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type ...
    Medical condition: Type II Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-002084-49 Sponsor Protocol Number: 06023GM-A Start Date*: 2006-09-13
    Sponsor Name:Belfast City Hospital Trust
    Full Title: Vascular function in impaired glucose tolerance - effect of pioglitazone
    Medical condition: Impaired glucose tolerance
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004669-40 Sponsor Protocol Number: SYR-322-TZD-009 Start Date*: 2006-03-15
    Sponsor Name:Takeda Global Research & Development Center, Inc.,
    Full Title: A multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diab...
    Medical condition: Type II diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-003238-32 Sponsor Protocol Number: v1 Start Date*: 2004-12-13
    Sponsor Name:Dept. of Clinical Pharmacology
    Full Title: Effect of pioglitazone on portal and systemic hemodynamics in patients with advanced cirrhosis
    Medical condition: Cirrhosis of the liver
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014830-10 Sponsor Protocol Number: GCPD_27july09 Start Date*: 2009-11-04
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse
    Full Title: Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone
    Medical condition: new onset diabetes mellitus after transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008127-15 Sponsor Protocol Number: 1264.3 Start Date*: 2010-07-16
    Sponsor Name:Boehringer Ingelheim RCV Gmbh
    Full Title: A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with p...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) EE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003111-58 Sponsor Protocol Number: AD-4833/TOMM40_301 Start Date*: 2013-09-20
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000725-54 Sponsor Protocol Number: PIOc/LAN07/TIF Start Date*: 2006-09-29
    Sponsor Name:TAKEDA
    Full Title: Double-blind, randomized, multicenter, parallel-group study to evaluate the effects of pioglitazone on metabolic syndrome in patients with type 2 diabetes treated with metformin
    Medical condition: Type 2 diabetes and metabolic syndrome IDF definition
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022491 Insulin resistant diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001929-31 Sponsor Protocol Number: ESCORPIO Start Date*: 2020-06-16
    Sponsor Name:Fundación Investigación Biomédica Hospital Ramón y Cajal
    Full Title: Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19.
    Medical condition: COVID-19 in patients with diabetes mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011675-79 Sponsor Protocol Number: ACTIM Start Date*: 2009-07-10
    Sponsor Name:CH-Versailles
    Full Title: A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR...
    Medical condition: chronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006025-73 Sponsor Protocol Number: 01-06-TL-322OPI-004 Start Date*: 2007-04-18
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Limited,
    Full Title: A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS® Pioglitazone HCl in Subjects ...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012614 Diabetes mellitus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) FR (Completed) BE (Completed) DE (Completed) NL (Prematurely Ended) AT (Completed) ES (Completed) GR (Prematurely Ended) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001442-35 Sponsor Protocol Number: PTZ Start Date*: 2021-06-04
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: A PHASE 2 MONOCENTRIC PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PIOGLITAZONE IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO
    Medical condition: NON SEGMENTAL VITILIGO WITH BSA BETWEEN 2% AND 50% AND A NON-SATISFACTORY RESPONSE (LESS THAN 10%) TO A PREVIOUS PHOTOTHERAPY CYCLE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10047643 Vitiligo vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005546-23 Sponsor Protocol Number: IRIS:IND#64,622 Start Date*: 2009-11-05
    Sponsor Name:Yale University School of Medicine
    Full Title: The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ische...
    Medical condition: Insulin resistance in patients who have had a stroke or transient ischaemic attack
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000461-18 Sponsor Protocol Number: PCOS/DM/1 Start Date*: 2005-03-31
    Sponsor Name:University of Hull
    Full Title: Study to Determine if The Cardiovascular risk indices in Type 2 diabetes are similar for Polycystic Ovarian Syndrome, and whether they may be modified by Therapy
    Medical condition: This is a randomised parallel controlled trial between patients with type 2 diabetes and those with polycystic ovarian syndrome. Patients will either be randomised to metformin or Pioglitazone.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000435-18 Sponsor Protocol Number: PCOS/IGT/1 Start Date*: 2005-03-31
    Sponsor Name:University of Hull
    Full Title: Study to Determine if The Cardiovascular risk indices in Impaired Glucose Tolerance are similar for Polycystic Ovarian Syndrome, and whether they may be modified by Therapy
    Medical condition: This is a randomised parallel controlled trial between patients with impaired glucose tolerance and those with polycystic ovarian syndrome. Patients will either be randomised to metformin or Piogli...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006225-14 Sponsor Protocol Number: ANRS HC 22 Start Date*: 2009-06-18
    Sponsor Name:ANRS
    Full Title: Essai clinique multicentrique, randomisé et contrôlé comparant l’efficacité de la pioglitazone versus placebo chez les patients avec hépatite virale chronique C de génotype non-2, non-3, insulinoré...
    Medical condition: Chronic hepatitis C Insulin resistance
    Disease: Version SOC Term Classification Code Term Level
    11.1 10008912 LLT
    11.1 10022489 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-004163-39 Sponsor Protocol Number: HSJD-LIT-05 Start Date*: 2005-11-14
    Sponsor Name:Hospital Sant Joan de Déu
    Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ...
    Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004463-30 Sponsor Protocol Number: ATS K015 Start Date*: 2005-06-22
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Effects of Pioglitazone in Combination with Atorvastatin in Comparison to Atorvastatin treatment alone on Intima-Media Thickness in patients at Risk for Vascular Complications
    Medical condition: Patients at risk for vascular complications (cardiovascular anamnesis, hypertension, hypercholesterolemia) and a carotid intima media thickness >= 0.8 mm at least at one side will be eligible for t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 01 23:41:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA